FrancophonIA/ELRC3.0 huggingface dataset:
English: Immediate packaging (blister foil)
Slovenian: Stična ovojnina (pretisni omot)
English: Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).
Slovenian: Zdravilo Rebetol je v kombinaciji z drugimi zdravili indicirano za zdravljenje kronične okužbe z virusom hepatitisa C (HCV) pri odraslih bolnikih (glejte poglavja 4.2, 4.4 in 5.1).
English: Rebetol oral solution is supplied in a concentration of 40 mg/mL.
Slovenian: Rebetol peroralna raztopina je na voljo v koncentraciji 40 mg/ml.
English: In a single dose, crossover study of ribavirin in healthy adult subjects, the capsule and oral solution formulations were found to be bioequivalent.
Slovenian: V navzkrižni študiji z enkratnim odmerkom ribavirina pri zdravih odraslih preiskovancih je bila za kapsule in peroralno raztopino dokazana bioekvivalenca.
English: Pancytopenia and bone marrow suppression have been reported in the literature to occur within 3 to 7 weeks after the administration of a peginterferon and Rebetol concomitantly with azathioprine.
Slovenian: V literaturi so poročali o pancitopeniji in supresiji kostnega mozga, ki sta se pojavili v 3 do 7 tednih po dajanju peginterferona in zdravila Rebetol sočasno z azatioprinom.
English: In the cases in which no specific dose recommendation is made, the following dose should be used: Patient weight: < 75 kg =1,000 mg and > 75 kg = 1,200 mg.
Slovenian: V primerih, kadar ni specifičnih priporočil glede odmerka, je treba pri bolnikih s telesno maso < 75 kg uporabiti odmerek 1.000 mg in pri bolnikih s telesno maso > 75 kg odmerek 1.200 mg.
English: Female: amenorrhea, menorrhagia, menstrual disorder, vaginal disorder, Male: testicular pain
Slovenian: ženske: amenoreja, menoragija, menstrualne motnje, bolezni nožnice; moški: bolečine v testisih
English: Table 4 Dosage Modification for Renal Impairment in Adult Patients Creatinine Clearance
Slovenian: Preglednica 4 Prilagoditev odmerka v primeru okvare ledvic pri odraslih bolnikih Očistek kreatinina
English: - The other ingredients are: sodium citrate, citric acid, anhydrous, sodium benzoate, glycerol, sucrose, sorbitol liquid (crystallising), propylene glycol, purified water, natural and artificial bubble gum flavouring
Slovenian: - Druge sestavine so natrijev citrat, brezvodna citronska kislina, natrijev benzoat, glicerol, saharoza, tekoči sorbitol (kristalizirajoči), propilenglikol, prečiščena voda, naravna in umetna aroma za žvečilne gumije
English: Table 3 Dosage Modification for Renal Impairment in Adult Patients Creatinine Clearance
Slovenian: Preglednica 3 Prilagoditev odmerka v primeru okvare ledvic pri odraslih bolnikih Očistek kreatinina
English: The study results are summarized in Table 7.
Slovenian: Povzetek izsledkov študije je podan v preglednici 7.
English: Twenty-four percent of children (11/46) treated for 24 weeks and 40 % of children (19/48) treated for 48 weeks had a > 15 percentile height-for-age decrease from pre-treatment to the end of 5 year long-term follow-up compared to pre-treatment baseline percentiles.
Slovenian: Štiriindvajsetim odstotkom otrok (11/46), zdravljenih 24 tednov, in 40 % otrok (19/48), zdravljenih 48 tednov, se je od časa pred zdravljenjem do konca 5-letnega dolgoročnega spremljanja telesna višina za starost zmanjšala za > 15 percentilov v primerjavi z izhodiščnim percentilom pred zdravljenjem.
English: - Breast-feeding.
Slovenian: - Dojenje.
English: There were some cases of more severe neutropenia in patients treated with Rebetol in combination with peginterferon alfa-2b (WHO grade 3: 39 of 186 [21 %]; and WHO grade 4: 13 of 186 [7 %]); WHO grade 3 leukopenia was also reported in 7 % of this treatment group.
Slovenian: Bilo je tudi nekaj primerov hujše nevtropenije (3. stopnje po WHO: 39 od 186 [21 %] in 4. stopnje po WHO: 13 od 186 [7 %]) med bolniki, zdravljenimi z zdravilom Rebetol v kombinaciji s peginterferonom alfa-2b; pri 7 % bolnikov iz te terapevtske skupine so poročali tudi o levkopeniji 3. stopnje po WHO.
English: LVL (≤600,000 IU/mL)
Slovenian: LVL (≤ 600 000 i.e./ml)
English: Consideration should be given to replacing zidovudine in a combination anti-retroviral treatment (ART) regimen if this is already established.
Slovenian: Pri zdravljenju z uveljavljeno kombinirano protivirusno shemo (ART) je treba premisliti o zamenjavi zidovudina.
English: Virological response by week 4 is defined as at least 1-log viral load decrease or undetectable levels of HCV-RNA.
Slovenian: Virološki odziv do 4. tedna je opredeljen kot zmanjšanje virusne obremenitve za najmanj 1-log ali nemerljive koncentracije HCV-RNA.
English: The haemolytic anaemia associated with Rebetol therapy may result in deterioration of cardiac function and/or worsening of pre-existing cardiac disease.
Slovenian: Hemolitična anemija, povezana z uporabo zdravila Rebetol, lahko poslabša delovanje srca in/ali že obstoječo srčno bolezen.
English: % (number) of patients peginterferon alfa-2b 1.5 µg/kg + Rebetol peginterferon alfa-2b 1 µg/kg + Rebetol peginterferon alfa-2a 180 µg + ribavirin
Slovenian: % (število) bolnikov peginterferon alfa-2b 1,5 µg/kg + zdravilo Rebetol peginterferon alfa-2b 1 µg/kg + zdravilo Rebetol peginterferon alfa-2a 180 µg + ribavirin
English: NR: Non-responder defined as serum/plasma HCV-RNA positive at the end of a minimum of 12 weeks of treatment.
Slovenian: NR: Neodzivni bolniki so opredeljeni kot tisti, ki imajo pozitiven izvid na serumsko ali plazemsko HCV-RNA ob koncu najmanj 12 tednov zdravljenja.
English: Rebetol must not be used by females who are pregnant (see sections 4.3 and 5.3).
Slovenian: Nosečnice ne smejo uporabljati zdravila Rebetol (glejte poglavji 4.3 in 5.3).
English: - Men:
Slovenian: - Moški:
English: - The active substance is ribavirin 40 mg/mL.
Slovenian: - Zdravilna učinkovina je ribavirin 40 mg/ml.
English: Rebetol contains sucrose and sorbitol
Slovenian: Zdravilo Rebetol vsebuje saharozo in sorbitol
English: The 10 mL oral dosing syringe consists of a natural polyethylene barrel, with a white polystyrene plunger rod.
Slovenian: 10 ml brizga za peroralno odmerjanje zdravila sestoji iz valjastega dela iz naravnega polietilena in iz belega polistirenskega bata.
English: At least 5 years of long-term follow-up was completed after treatment in 462 patients and 327 patients, respectively.
Slovenian: 462 bolnikih oziroma pri 327 bolnikih je bilo opravljeno najmanj 5-letno dolgoročno spremljanje.
English: The additional following side effectshave occurred with the combination of this medicineand an alpha interferon product in adults but not in children:
Slovenian: Naslednji dodatni pogosto poročani neželeni učinki so se pojavili pri uporabi kombinacije tega zdravila in zdravil, ki vsebuje interferon alfa, pri odraslih, vendar ne pri otrocih:
English: Ribavirin has been shown to produce high inter- and intra-subject pharmacokinetic variability following single oral doses (intrasubject variability of approximately 30 % for both AUC and Cmax), which may be due to extensive first pass metabolism and transfer within and beyond the blood compartment.
Slovenian: Pokazalo se je, da ima ribavirin veliko inter- in intra-individualno variabilnost farmakokinetičnih parametrov po enkratnem peroralnem odmerku (variabilnost pri posamezniku je bila približno 30 % tako za AUC kot za Cmax).
English: In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and Rebetol, 6 % discontinued therapy due to adverse reactions.
Slovenian: V kliničnih preskušanjih pri 118 otrocih in mladostnikih, starih od 3 do 16 let, zdravljenih s kombinacijo interferona alfa-2b in zdravila Rebetol, je bilo pri 6 % zdravljenje ukinjeno zaradi neželenih učinkov.
English: B. While keeping the tip in the liquid, pull the rod out.
Slovenian: B. Vrh brizge držite v tekočini in medtem vlecite bat iz brizge.
English: Ribavirin is embryotoxic or teratogenic, or both, at doses well below the recommended human dose in all animal species in which studies have been conducted.
Slovenian: Ribavirin je bil pri vseh živalskih vrstah, pri katerih so bile opravljene študije, embriotoksičen, teratogen ali oboje, v odmerkih, precej manjših od priporočenega odmerka za človeka.
English: By Week 12 (n=215) HCV-RNA negative or ≥ 2 log decrease in viral load
Slovenian: Do 12 tedna (n = 215) Negativen izvid testa na HCV-RNA ali zmanjšanje virusnega bremena za ≥ 2 log
English: This medicine contains sucrose and sorbitol, these are types of sugars.
Slovenian: To zdravilo vsebuje saharozo in sorbitol, ki sta sladkorja.
English: Upon multiple dosing, ribavirin accumulates extensively in plasma with a six-fold ratio of multiple-dose to single-dose AUC12hr.
Slovenian: Po večkratnem odmerjanju se ribavirin obsežno kopiči v plazmi, s šestkratnim razmerjem med vrednostma AUC12 ur za večkratno in za enkratno odmerjanje.
English: - Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).
Slovenian: - Hemoglobinopatije (npr. talasemija, anemija srpastih celic).
English: For HCV/HIV co-infected patients receiving Rebetol in combination with peginterferon alfa-2b, other adverse reactions (that were not reported in mono-infected patients) which have been reported in the studies with a frequency > 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
Slovenian: Bolniki, ki so bili sočasno okuženi s HCV in HIV in so prejemali zdravilo Rebetol v kombinaciji s peginterferonom alfa-2b, so imeli naslednje dodatne neželene učinke, ki jih niso opažali pri bolnikih s samo eno okužbo, v študijah pa so o njih poročali s pogostnostjo > 5 %: peroralna kandidoza (14 %), pridobljena lipodistrofija (13 %), zmanjšano število limfocitov CD4 (8 %), zmanjšan apetit (8 %), zvišana vrednost gama glutamiltransferaze (9 %), bolečine v hrbtu (5 %), zvišana vrednost amilaze v krvi (6 %), zvišana koncentracija mlečne kisline v krvi (5 %), citolitični hepatitis (6 %), zvišana vrednost lipaze (6 %) in bolečine v udih (6 %).
English: HVL (>600,000 IU/mL)
Slovenian: HVL (> 600 000 i.e./ml)
English: Psychiatric disorders Very common:
Slovenian: Psihiatrične motnje Zelo pogosti:
English: No response at Treatment Week
Slovenian: Ni odziva v tednu zdravljenj a
English: Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/Rebetol therapy.
Slovenian: Nekateri podatki kažejo, da obstaja pri bolnikih, ki so sočasno okuženi z virusoma HIV in HCV ter prejemajo ART z abakavirjem, tveganje za manjšo stopnjo odziva na zdravljenje s pegiliranim interferonom in zdravilom Rebetol.
English: • have any blood disorders, such as anaemia (low blood count), thalassemia, sickle-cell anaemia.
Slovenian: • če imate katero od krvnih bolezni, kot so anemija (nizko število krvnih celic), talasemija,
English: • Haemoglobin
Slovenian: • hemoglobin
English: The pharmacokinetics of Rebetol (dose-normalized) in this trial was similar to those reported in a prior study of Rebetol in combination with interferon alfa-2b in children and adolescent patients and in adult patients.
Slovenian: Farmakokinetika zdravila Rebetol (pri uporabi normaliziranega odmerka) v tem preskušanju je bila podobna farmakokinetiki, ugotovljeni v prejšnji študiji uporabe zdravila Rebetol v kombinaciji z interferonom alfa-2b pri otrocih in mladostnikih ter pri odraslih bolnikih.
English: Eleven percent of children (5/46) treated for 24 weeks and 13 % of children (6/48) treated for 48 weeks were observed to have a decrease from pre-treatment baseline > 30 height-for-age percentiles to the end of the 5 year long-term follow-up.
Slovenian: Pri enajstih odstotkih otrok (5/46), zdravljenih 24 tednov, in 13 % otrok (6/48), zdravljenih 48 tednov, so od časa pred zdravljenjem do konca 5-letnega dolgoročnega spremljanja opazili zmanjšanje > 30 percentilov telesne višine za starost.
English: The exacerbation of anaemia due to Rebetol has been reported when zidovudine is part of the regimen used to treat HIV although the exact mechanism remains to be elucidated.
Slovenian: Kadar je bil zidovudin vključen v shemo zdravljenja okužbe s HIV, so poročali o poslabšanju anemije zaradi uporabe zdravila Rebetol, čeprav natančen mehanizem tega pojava ni znan.
English: The combination of Rebetol and other medicines is used to treat adult patients who have chronic hepatitis C (HCV).
Slovenian: Kombinacija zdravila Rebetol in drugih zdravil se uporablja za zdravljenje odraslih bolnikov s kronično okužbo z virusom hepatitisa C (HCV).
English: Carrat F, Bani-Sadr F, Pol S et al. JAMA 2004; 292(23): 2839-2848.
Slovenian: JAMA 2004; 292(23): 2839-2848.
English: Each Rebetol capsule contains 40 mg of lactose.
Slovenian: Ena kapsula zdravila Rebetol vsebuje 40 mg laktoze.
English: Name and address of the manufacturer responsible for batch release for the oral solution
Slovenian: Ime in naslov izdelovalca, odgovornega za sproščanje serij za peroralno raztopino
English: The rod is marked with 0.5 mL markings starting at 1.5 mL (at the very top of the rod) and ending at 10 mL.
Slovenian: Bat ima oznake z razmiki po 0,5 ml, v razponu od 1,5 ml (čisto na vrhu bata) do 10 ml.
English: If week 12 HCV-RNA is positive and decreased ≥ 2 log10 from baseline, then retest HCV-RNA at week 24 and if positive, patients to stop therapy.
Slovenian: Če pa je izvid določanja HCV-RNA v 12. tednu pozitiven in za ≥ 2 log10 manjši od začetne vrednosti, pa v 24. tednu ponovno opravite določanje vrednosti HCV-RNA in če je izvid pozitiven, naj bolnik preneha z zdravljenjem.
English: In females of childbearing potential, Rebetol must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Slovenian: Zdravljenja z zdravilom Rebetol ne smete uvesti, dokler ne dobite negativnega izvida testa nosečnosti tik pred začetkom zdravljenja.
English: The combination of Rebetol and other medicines is used to treat patients who have chronic hepatitis C (HCV).
Slovenian: Kombinacija zdravila Rebetol in drugih zdravil se uporablja za zdravljenje bolnikov s kronično okužbo z virusom hepatitisa C (HCV).
English: nd dose reduction of Rebetol is by an additional 200 mg/day.
Slovenian: Če je potrebno, lahko opravite tudi drugo zmanjšanje odmerka zdravila Rebetol za dodatnih 200 mg/dan.
English: Number of 200 mg capsules
Slovenian: Število 200 mg kapsul
English: Haematological abnormalities were more frequently reported in patients receiving Rebetol in combination with peginterferon alfa-2b when compared to patients receiving Rebetol in combination with interferon alfa-2b.
Slovenian: O hematoloških motnjah so poročali pogosteje pri bolnikih, ki so prejemali zdravilo Rebetol v kombinaciji s peginterferonom alfa-2b, kot pri tistih, ki so prejemali zdravilo Rebetol v kombinaciji z interferonom alfa-2b.
English: Response to the treatment was measured by Sustained Virologic Response (SVR) which is defined as undetectable HCV-RNA at 24 weeks post-treatment (see Table 9).
Slovenian: Odziv bolnikov na zdravljenje so merili na podlagi trajnega virološkega odziva (SVRSustained Virologic Response), ki je opredeljen kot nemerljiva koncentracija HCV-RNA v 24. tednu po koncu zdravljenja (glejte preglednico 9).
English: Additionally, patients receiving zidovudine with ribavirin in combination with alpha interferons could be at increased risk of developing anaemia (low number of red blood cells).
Slovenian: Pri bolnikih zdravljenih s kombinirano terapijo interferonov alfa z ribavirinom v kombinaciji z zidovudinom se lahko poveča verjetnost za razvoj anemije (majhno število rdečih krvnih celic).
English: During combination therapy for up to 48 weeks with pegylated interferon alfa-2b and Rebetol, growth inhibition was observed that resulted in reduced height in some patients (see section 4.4).
Slovenian: V času kombinirane terapije s pegiliranim interferonom alfa-2b in zdravilom Rebetol, ki je trajala do 48 tednov, so opazili zastoj rasti, ki je pri nekaterih bolnikih povzročil manjšo telesno višino (glejte poglavje 4.4).
English: The population enrolled mainly consisted in children with mild to moderate hepatitis C. The population enrolled mainly consisted in children with mild to moderate hepatitis C. In the two multicentre trials, sustained virological response rates in children and adolescents were similar to those in adults (see Table 7).
Slovenian: Populacija je vključevala predvsem otroke z blagim do zmernim hepatitisom C. V dveh multicentričnih študijah je bil delež trajnega virološkega odziva pri otrocih in mladostnikih podoben tistemu pri odraslih (glejte preglednico 7).
English: Very rarely reported side effects (may affect up to 1 in 10,000 people): suicide, stroke (cerebrovascular events).
Slovenian: Zelo redko poročani neželeni učinki (pojavijo se lahko pri največ 1 od 10.000bolnikov): samomor, možganska kap (možganskožilni dogodki).
English: Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).
Slovenian: Zdravilo Rebetol je v kombinaciji z drugimi zdravili indicirano za zdravljenje kronične okužbe z virusom hepatitisa C (HCV) pri pediatričnih bolnikih (otrocih, starih 3 leta ali več, in mladostnikih), ki predhodno še niso bili zdravljeni in nimajo jetrne dekompenzacije (glejte poglavja 4.2, 4.4 in 5.1).
English: Standard haematologic tests, blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) and pregnancy tests must be conducted in all patients prior to initiating therapy.
Slovenian: Pred pričetkom zdravljenja morate pri vseh bolnikih opraviti standardne hematološke, biokemične preiskave krvi (celotno krvno sliko in diferencialno krvno sliko, število trombocitov, določanje vrednosti elektrolitov in serumskega kreatinina, teste delovanja jeter, določanje vrednosti sečne kisline) in test nosečnosti.
English: Caution should be taken in HIV-positive subjects co-infected with HCV who receive nucleoside reverse transcriptase inhibitor (NRTI) treatment (especially ddI and d4T) and associated interferon alfa/ribavirin treatment.
Slovenian: Pri bolnikih s pozitivnim izvidom na HIV in sočasno okužbo s HCV, ki se zdravijo z nukleozidnim zaviralcem reverzne transkriptaze (NRTI - nucleoside reverse transcriptase inhibitor) (posebno ddI in d4T) v povezavi z interferonom alfa in ribavirinom, je potrebna previdnost.
English: particularly Genotype 1, in which the relapse rate was reduced by 30 % compared with interferon alfa-2b monotherapy.
Slovenian: To je veljalo za vse HCV genotipe, a še posebej za genotip 1, kjer se je delež ponovitev zmanjšal za 30 % v primerjavi z monoterapijo z interferonom alfa-2b.
English: The response to treatment in both of these trials is presented in Table 11.
Slovenian: V preglednici 11 je predstavljen odziv bolnikov na zdravljenje pri obeh preskušanjih.
English: Discontinue breast-feeding before starting to take this medicine.
Slovenian: Pred začetkom jemanja tega zdravila morate prenehati z dojenjem.
English: Therefore, do not drive or use machines if you become tired, sleepy, or confused from this treatment.
Slovenian: Če zaradi tega zdravljenja postanete utrujeni, zaspani ali zmedeni, ne vozite in ne upravljajte s stroji.
English: The sustained response at the end of follow-up was significantly increased by the addition of Rebetol to interferon alfa-2b (41 % vs 16 %, p < 0.001).
Slovenian: Trajni odziv na koncu spremljanja bolnikov je bil bistveno večji (41 % proti 16 %, p < 0,001) zaradi dodatka zdravila Rebetol interferonu alfa-2b.
English: Please refer to the corresponding SmPC of medicinal products used in combination with Rebetol as some combination regimens do not adhere to the Rebetol dosing guidance provided in Table 1.
Slovenian: Prosimo, glejte ustrezne povzetke glavnih značilnosti zdravil, uporabljenih v kombinaciji z zdravilom Rebetol, ker za nekatere kombinirane sheme ne veljajo smernice za odmerjanje zdravila Rebetol, navedene v preglednici 1.
English: (-0.3 for Metavir and -1.2 for Ishak) and stable (-0.1 for Metavir and -0.2 for Ishak) among non-responders.
Slovenian: Ta upad je bil statistično značilen pri bolnikih, ki so se odzvali na zdravljenje (-0,3 pri oceni po Metavirju in -1,2 pri oceni po Ishaku) in stabilen (-0,1 pri oceni po Metavirju in -0,2 pri oceni po Ishaku) pri tistih, ki se niso odzvali na zdravljenje.
English: Adverse reactions reported with a > 10 % incidence in adult patients treated with Rebetol capsules in combination with interferon alfa-2b or pegylated interferon alfa-2b for one year have also been reported in children and adolescents.
Slovenian: O neželenih učinkih, poročanih s pojavnostjo > 10 % pri odraslih bolnikih, ki so se eno leto zdravili z zdravilom Rebetol kapsule v kombinaciji z interferonom alfa-2b ali pegiliranim interferonom alfa-2b, so poročali tudi pri otrocih in mladostnikih.
English: Dose modification for adverse reactions
Slovenian: Prilagoditev odmerka v primeru neželenih učinkov
English: Genotype 1* By Week 4*** (n= 950) HCV-RNA negative
Slovenian: Do 4. tedna*** (n = 950) Negativen izvid testa na HCV-RNA
English: This medicinein combination with peginterferon alfa-2b or interferon alfa-2b may also cause: dark, cloudy or abnormally coloured urine, difficulty breathing, changes in the way your heart beats, chest pain, pain down left arm, jaw pain, loss of consciousness, loss of use, drooping or loss of power of facial muscles, loss of feeling sensation, loss of vision.
Slovenian: To zdravilo v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b lahko povzroči tudi: temen, moten ali nenormalno obarvan urin, težave z dihanjem, spremembe srčnega utripa, bolečine v prsih, bolečine navzdol po levi roki, bolečine v čeljustih, izgubo zavesti, nezmožnost premikanja, povešanje ali izgubo moči obraznih mišic, izgubo občutka za dotik, izgubo vida.
English: Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3
Slovenian: Izguba telesne mase in zastoj rasti sta bila zelo pogosta med zdravljenjem (ob koncu zdravljenja je znašalo povprečno zmanjšanje telesne mase 15 percentilov, višine pa 8 percentilov glede na izhodiščno vrednost) in tudi njihova hitrost rasti je bila zmanjšana (pri 70 % bolnikov se je upočasnila za do 3 percentile).
English: Table 14 Sustained virological response in previously untreated children and adolescents Rebetol 15 mg/kg/day interferon alfa-2b 3 MIU/m2 3 times a week
Slovenian: Preglednica 14 Trajni virološki odziv pri predhodno nezdravljenih otrocih in mladostnikih Zdravilo Rebetol 15 mg/kg na dan interferon alfa-2b 3 mio i.e./m2 3-krat na teden
English: In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when Rebetol is administered.
Slovenian: Pri bolnikih, pozitivnih na HIV, ki se zdravijo po shemi NRTI, mora zdravnik pri sočasnem zdravljenju z zdravilom Rebetol skrbno spremljati pokazatelje mitohondrijske toksičnosti in laktacidoze.
English: Table 8 Virologic Response at End of Treatment, Sustained Virologic Response and Relapse by HCV Genotype and Viral Load* Rebetol 800-1,400 mg/day plus peginterferon alfa-2b 1.5 g/kg once weekly End of Treatment Response
Slovenian: Preglednica 8 Virološki odziv ob koncu zdravljenja, trajni virološki odziv in ponovitev bolezni po HCV genotipih in virusni obremenitvi* Zdravilo Rebetol v odmerku 800 do 1.400 mg na dan plus peginterferon alfa-2b v odmerku 1,5 g/kg enkrat na teden odziv ob koncu zdravljenja trajni virološki odziv ponovitev bolezni